{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.65","value":"75.7"},{"groupId":"OG001","spread":"18.54","value":"74.8"}]}],"title":"Thermometer Score, Day 1; n=74, 79"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.76","value":"74.4"},{"groupId":"OG001","spread":"19.94","value":"69.8"}]}],"title":"Thermometer Score, Washout; n=60, 63"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.19","value":"71.3"},{"groupId":"OG001","spread":"22.55","value":"65.1"}]}],"title":"Thermometer Score, End of Study; n=51, 45"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.25331","value":"0.7625"},{"groupId":"OG001","spread":"0.22946","value":"0.7664"}]}],"title":"Utility Score, Day 1; n=76, 81"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.20776","value":"0.8103"},{"groupId":"OG001","spread":"0.26826","value":"0.7595"}]}],"title":"Utility Score, Washout; n=61, 67"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.21324","value":"0.7487"},{"groupId":"OG001","spread":"0.29635","value":"0.6325"}]}],"title":"Utility Score, End of Study; n=52, 47"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"The EQ-5D is a participant-answered questionnaire measuring 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D has two separate components: utility score and thermometer score. The EQ-5D total utility score ranges from 0 (worst health state) to 1 (perfect health state); 1 reflects the best outcome. The thermometer score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state).","dispersionType":"Standard Deviation","groups":[{"description":"Period 1: Participants received 4 overencapsulated capsules of sunitinib, each containing 12.5 milligrams (mg) of sunitinib, once daily (OD) orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Period 1 was followed by a 2-week wash-out period in which no treatment was given. Period 2: Participants received 4 overencapsulated tablets of pazopanib, each containing 200 mg of pazopanib, OD orally for 10 weeks. Study drugs were taken without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drugs were taken remained relatively constant.","id":"OG000","title":"Sunitinib 50 mg Followed by Pazopanib 800 mg"},{"description":"Period 1: Participants received 4 overencapsulated tablets of pazopanib, each containing 200 mg of pazopanib, OD orally for 10 weeks. Period 1 was followed by a 2-week wash-out period in which no treatment was given. Period2: Participants received 4 overencapsulated capsules of sunitinib, each containing 12.5 mg of sunitinib, OD orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Study drugs were taken without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drugs were taken remained relatively constant.","id":"OG001","title":"Pazopanib 800 mg Followed by Sunitinib 50 mg"}],"paramType":"MEAN","populationDescription":"Safety-Randomized Study Population. Participants (par.) who received mixed treatment within a period were excluded. Only those par. contributing data at the indicated time points were evaluated. In some instances, par. may have contributed data for one score, but not the other; thus, the number of par. analyzed reflects the entire population.","reportingStatus":"POSTED","timeFrame":"Day 1 (Period 1 Pre-dose); during 2-week Wash-out Period (Study Weeks 11 and 12); and End of Study (Week 10 of Period 2 [Study Week 22])","title":"Quality of Life as Assessed by the EuroQoL-5 Dimensions (EQ-5D) Thermometer and Utility Scores","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}